

Supplemental Digital Content 1 (Methods)

A validated LC/MS/MS assay analyzed PBMC tenofovir di-phosphate (TFV-DP) and emtricitabine tri-phosphate (FTC-TP) levels from lysed intracellular matrix, with a linear range of 2.5-2000 femtomole (fmol)/sample for TFV-DP and 0.1-200 picomole (pmol)/sample for FTC-TP.¹⁶ Two million total cells were typically extracted, constituting the sample, and results were corrected for cell viability and normalized to fmol/million viable cells.¹⁴

Supplemental Digital Content 2 (Methods)

Perceived HIV risk was assessed at screening with the item; "Do you think in your lifetime you will become infected with HIV?" with the following response options: "No, I will not"; "It could happen"; "It probably will happen"; and "It almost certainly will happen". *Perceived study arm assignment* was assessed at week 12 with options of "I strongly think I am in the Truvada (or placebo) group"; "I somewhat think I am in the Truvada (or placebo) group"; and "don't know." The two Truvada and two placebo categories (strongly/somewhat think) were grouped together for analysis. *Perception of PrEP efficacy* was also evaluated at the 12 week visit with the question, "How good do you think Truvada is in preventing HIV infection?" Responses were based on a 0-10 scale where 10 means it prevents HIV infection all the time, 0 means it doesn't prevent HIV infection at all, and 5 means it prevents HIV half of the time.